A DNA Repair Gene Went Rogue, Exposing Cancer's Hidden Weakness

You know that diligent friend who's almost too helpful? The one who tidies your desk and accidentally throws out your car keys? Turns out, our own cells have one of those.

Meet EXO1, a gene usually lauded as a DNA repair superhero. Its job? To snip away damaged bits of our genetic code, keeping everything running smoothly. A real good guy. But a new study from Penn State College of Medicine just dropped a bombshell: when cells make too much EXO1, this helpful little gene goes rogue. Instead of fixing DNA, it starts hacking at it indiscriminately, causing the kind of damage that practically screams "cancer."

The Overachiever Gene That Breaks Things

Imagine tiny scissors meticulously trimming frayed edges. That's EXO1 at its best. Now imagine those scissors in the hands of a caffeinated toddler. That's too much EXO1. It goes on a rampage, cutting DNA it absolutely should not, leading to genomic instability — a hallmark of cancer.

This isn't some niche problem, either. The research, published in Nature Communications, found that EXO1 is overactive in a staggering 20% to 30% of breast and ovarian cancers. It’s also lurking in melanoma, testicular, cervical, and various liver cancers. So, this overzealous gene is a surprisingly common troublemaker.

Even more intriguing? Cancer cells with high EXO1 levels start behaving eerily like cells with BRCA mutations. Those are the well-known genetic changes that significantly increase the risk of inherited breast and ovarian cancers. The kicker? This BRCA-like behavior happened even when the actual BRCA mutations were nowhere to be found. It’s like a mimic, but far more sinister.

A New Target for Smarter Treatments

This discovery isn't just a fascinating biological quirk; it's a potential game-changer for treatment. Tumors with elevated EXO1 levels responded to therapies in a way that mirrored BRCA-mutant cancers. This means drugs typically reserved for BRCA patients, which often come with fewer side effects, could potentially treat a much wider range of cancers.

George-Lucian Moldovan, a professor at Penn State and the study's senior author, noted that EXO1 levels could become a vital predictor for which patients will benefit from specific chemotherapy drugs. This opens the door for more personalized — and less brutal — treatment plans. Imagine getting a targeted therapy without having the specific mutation it was designed for. Because apparently, that's where we're headed.

The team dug into The Cancer Genome Atlas data, confirming EXO1's overproduction across many cancer types, especially in aggressive basal-like breast cancer. Then, in lab tests, they cranked up EXO1 in human cancer cells. They even created a disabled version to prove that the damage came from the gene's activity, not just its presence. Turns out, too much EXO1 makes new DNA unstable, creating gaps and breaks that essentially wear away our genetic material.

Lead author Alexandra Nusawardhana explained that this EXO1 overdrive creates and piles up harmful DNA lesions, like double-strand breaks. And that's likely what makes these tumors more susceptible to chemotherapy and more prone to cell death. It’s a weakness created by the cancer itself, just waiting to be exploited.

So, why does too much EXO1 act like a BRCA mutation? BRCA genes usually protect DNA during replication. When they're mutated, that protection is lost. This study showed that an overabundance of EXO1 can simply overpower these protective systems, even when BRCA genes are doing their job. It teams up with another protein, MRE11, to create even larger, more dangerous DNA breaks. As Moldovan put it, this overexpression does "exactly what the loss of the BRCA pathway does."

Since these high-EXO1 tumors mimicked BRCA-mutant ones, the researchers tested olaparib, a drug commonly used for BRCA-mutant cancers. The results were clear: tumors with high EXO1 were incredibly sensitive to it. They also responded well to cisplatin, a standard chemotherapy drug, suggesting that lower, less toxic doses could be effective.

Moldovan believes that because EXO1 overexpression is more common than BRCA mutations, it could become a crucial tool for guiding treatment choices. His vision for the future? Treating cancers based on the genetic changes within the tumors, not just where they popped up in the body. And if that's not enough to make you want to tell someone about it, they're already planning clinical trials. Good news, indeed.

The nuclease EXO1 promotes genomic instability by degrading nascent DNA in BRCA-proficient cells - Nature Communications, 2026